GENENTECH, INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 1976-01-01
- Employees
- 11.1K
- Market Cap
- -
- Website
- http://www.gene.com
Safety and Pharmacokinetics of DMUC5754A Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer
- First Posted Date
- 2011-04-15
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 77
- Registration Number
- NCT01335958
GDC-0980 in Combination With a Fluoropyrimidine, Oxaliplatin, and Bevacizumab in Patients With Advanced Solid Tumors
Phase 1
Completed
- Conditions
- Solid Cancers
- Interventions
- First Posted Date
- 2011-04-11
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 41
- Registration Number
- NCT01332604
A Study of the Safety and Pharmacology of GDC-0980 in Combination With Either Paclitaxel and Carboplatin (With or Without Bevacizumab) or Pemetrexed and Cisplatin in Patients With Solid Tumors
Phase 1
Completed
- Conditions
- Solid Cancers
- Interventions
- First Posted Date
- 2011-02-23
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 75
- Registration Number
- NCT01301716
A Study of Obinutuzumab (GA101; RO5072759) in Combination With Chemotherapy in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL) (GALTON)
Phase 1
Completed
- Conditions
- Lymphocytic Leukemia, Chronic
- Interventions
- First Posted Date
- 2011-02-21
- Last Posted Date
- 2017-02-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 41
- Registration Number
- NCT01300247
A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NHL) and in Combination With Endocrine Therapy in Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Phase 1
Terminated
- Conditions
- Solid CancersNon-Hodgkin's Lymphoma
- Interventions
- First Posted Date
- 2011-02-15
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 674
- Registration Number
- NCT01296555
- Locations
- 🇺🇸
Univ of Chicago, Chicago, Illinois, United States
🇺🇸Mary Crowley Cancer Rsch Ctr, Dallas, Texas, United States
🇺🇸Baylor Sammons Cancer Center, Dallas, Texas, United States
A Study to Evaluate the Efficacy, Response Duration and Safety of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine Treatment (H1)
- First Posted Date
- 2011-02-09
- Last Posted Date
- 2013-10-11
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 323
- Registration Number
- NCT01292473
A Study of Escalating Doses of Polatuzumab Vedotin in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma and Chronic Lymphocytic Leukemia and Polatuzumab Vedotin in Combination With Rituximab in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma
Phase 1
Completed
- Conditions
- Non-Hodgkins LymphomaChronic Lymphocytic Leukemia
- Interventions
- First Posted Date
- 2011-02-07
- Last Posted Date
- 2017-06-16
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 95
- Registration Number
- NCT01290549
- Locations
- 🇺🇸
M.D Anderson Cancer Center; Oncology, Houston, Texas, United States
🇺🇸Florida Cancer Specialists; Sarasota, Sarasota, Florida, United States
🇫🇷Centre Hospitalier Regional Universitaire de Lille, Lille, France
A Study of the Efficacy and Safety of Omalizumab (Xolair) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptomatic Despite Antihistamine (H1) Treatment
- First Posted Date
- 2011-02-01
- Last Posted Date
- 2013-11-27
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 319
- Registration Number
- NCT01287117
A 3-Part Study to Determine the Relative Bioavailability of Capsule and Tablet Formulations of GDC-0980, the Effect of Food, and the Effect of Rabeprazole on the Pharmacokinetics of the Tablet
- First Posted Date
- 2011-02-01
- Last Posted Date
- 2022-12-13
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 46
- Registration Number
- NCT01287091
- Locations
- 🇺🇸
Investigational Site, Austin, Texas, United States
A Study of the Safety and Pharmacokinetics of Escalating Doses of DSTP3086S in Patients With Metastatic Castration-Resistant Prostate Cancer
- First Posted Date
- 2011-01-26
- Last Posted Date
- 2016-10-04
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 84
- Registration Number
- NCT01283373
© Copyright 2025. All Rights Reserved by MedPath